Kiniksa Pharmaceuticals (NASDAQ:KNSA) International, plc, a pharmaceutical company previously known as Kiniksa Pharmaceuticals, Ltd., has completed a reorganization that shifts its place of incorporation from Bermuda to the United Kingdom. The transaction, which was effective as of Thursday, involved a court-approved scheme of arrangement and was sanctioned by the Supreme Court of Bermuda on June 14, 2024.
The reorganization, or "Redomiciliation," resulted in the exchange of shares where Kiniksa Bermuda shareholders received equivalent shares in the newly formed Kiniksa Pharmaceuticals International, plc.
Specifically, for each Kiniksa Bermuda Class A, Class A1, Class B, and Class B1 common shares held, shareholders received an equal number of Class A Ordinary Shares, Class A1 Ordinary Shares, Class B Ordinary Shares, and Class B1 Ordinary Shares, respectively, of the new UK-incorporated entity.
As part of the reorganization, certain shareholders received Depositary Receipts due to transfer restrictions on the Company Shares. These receipts, issued by Computershare Trust Company, N.A., allow the underlying shares to be held initially by the Depositary and then transferred into The Depository Trust Company (DTC) system without incurring UK stamp duty or SDRT.
The Class A Ordinary Shares began trading on the Nasdaq Global Select Market under the ticker "KNSA" on Friday, the same symbol the company's shares traded under prior to the reorganization.
Kiniksa Pharmaceuticals International, plc has also adopted new Articles of Association and entered into indemnification agreements with its directors and executive officers. The company's existing equity incentive plans have been assumed, with outstanding equity awards converted on a one-for-one basis to awards with respect to ordinary shares of the same class.
The executive officers and directors of Kiniksa Bermuda prior to the reorganization have assumed the same roles in the new UK entity, with the board of directors maintaining its previous structure and committee memberships.
This move does not change the company's operational headquarters, which remains in Lexington, Massachusetts, nor does it alter the executive team or board of directors. The reorganization is reported to be in accordance with Rule 12g-3(f) under the Exchange Act, with the Class A Ordinary Shares deemed to be registered under Section 12(b) of the Exchange Act.
This article is based on a press release statement and information from a SEC filing.
In other recent news, Kiniksa Pharmaceuticals saw a significant 85% surge in net product revenue in Q1 2024, primarily from its leading drug, ARCALYST, which totaled $78.9 million. The company also announced a full-year sales target for ARCALYST between $370 million and $390 million. In addition, Kiniksa plans to commence a Phase 2b trial for Abiprubart in treating Sjögren’s Disease in the latter half of the year.
In recent developments, Wells Fargo (NYSE:WFC) initiated coverage on shares of Kiniksa Pharmaceuticals, assigning an Overweight rating with a price target of $34.00. The firm cited the company's growth potential, particularly focusing on the anticipated revenue of $385 million for the year 2024 from a drug. Wells Fargo's positive outlook is based on expected favorable data from a competitor's drug study, which could suggest a strong performance for Kiniksa's apiprubart.
The analyst from Wells Fargo also highlighted the potential of Kiniksa's drug, apiprubart, linked to upcoming 48-week data for Novartis (SIX:NOVN)' iscalimab in Sjögren's syndrome. Furthermore, continued revenue beats from Kiniksa's Arcalyst could further drive the company's performance in the medium term.
InvestingPro Insights
In light of Kiniksa Pharmaceuticals' recent corporate reorganization, investors may find the following metrics and tips from InvestingPro particularly relevant. Kiniksa Pharmaceuticals (KNSA) holds a market capitalization of $1.33 billion, showcasing its significant presence in the pharmaceutical industry.
With a striking revenue growth of 27.69% over the last twelve months as of Q1 2024, the company demonstrates a robust upward trajectory in sales. Moreover, Kiniksa's price to book ratio stands at 3.07, indicating investors' confidence in the value of the company's assets relative to its share price.
Key InvestingPro Tips suggest a positive outlook for Kiniksa Pharmaceuticals. Analysts anticipate sales growth in the current year, which aligns with the strong revenue growth observed. Furthermore, Kiniksa is trading at a high earnings multiple of 150.73, which may reflect market expectations of future growth.
Notably, the company's liquid assets exceed its short-term obligations, indicating a solid financial position for meeting its immediate liabilities. Kiniksa has been profitable over the last twelve months, and analysts predict the company will maintain profitability this year. It's important to note that Kiniksa does not pay a dividend, which could be a consideration for income-focused investors.
For those interested in diving deeper into Kiniksa Pharmaceuticals' financial health and future prospects, there are additional InvestingPro Tips available at https://www.investing.com/pro/KNSA. Use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and explore a total of 6 additional tips that could further inform your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.